Cited Literature

Return to HTAJ Home Page
Return to Title/Abstract/Chapter Table of Contents
Return to Chapter 7: Editorial Conclusions

1. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321-1327.
2. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association between human tumor colony-forming assay results and response to an individual patient's tumor to chemotherapy. Am J Med 1981; 70: 1027-1032.
3. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-139.
4. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther 1997; 76: 177-185.
5. Jaffrezou JP, Bettaieb A, Levade T, Laurent G. Antitumor agent-induced apoptosis in myeloid leukemia cells: a controlled suicide. Leuk Lymphoma 1998; 29: 453-463.
6. Selby P, Buick RN, Tannock I. A critical appraisal of the "human tumor stem cell assay". New Engl J Med 1983; 308: 129-134.
7. Lieber MM, Kovach JS. Soft agar colony formation assay for chemotherapeutic sensitivity of human solid tumors. Mayo Clin Proc 1982; 57: 527-528.
8. Tanigawa N, Kern DH, Kikasa Y, Morton DL. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res 1982; 42: 2159-2164.
9. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82: 582-588.
10. Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy: the Kern and DISC assays. Oncology (U S A ) 1992; 5: 93-103;.
11. Fernandez-Trigo V, Shamsa F, Vidal-Jove J, Kern DH, Sugarbaker PH. Prognostic implications of chemoresistance-sensitivity assays for colorectal and appendiceal cancer. Am J Clin Oncol 1995; 18: 454-460.
12. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998; 70: 392-397.
13. Eltabbakh GH. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol 2000; 73: 148-152.
14. Ajani JA, Baker FL, Spitzer G, et al. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol 1987;
5: 1912-1921.
15. Weisenthal LM, Shoemaker RH, Marsden JA, Dill PL, Baker JA, Moran EM. In vitro chemosensitivity assay based on the concept of total tumor cell kill. Recent Results Cancer Res 1984; 94: 161-173.
16. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69: 615-632.
17. Weisenthal LM. Cell culture assays for hematologic neoplasms based on the concept of total tumor cell kill. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Langhorne, PA: Harwood Academic Publishers, 1993: 415-432.
18. Weisenthal LM. Clinical correlations for cell culture assays based on the concept of total tumor cell kill. Contrib Gynecol Obstet 1994; 19: 82-90.
19. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983; 43: 749-757.
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
21. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984; 62: 338-343.
22. Garewal HS, Ahmann FR, Schifman RB, Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst 1986; 77: 1039-1045.
23. Sevin B-U, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988; 31: 191-204.
24. Rotman B, Teplitz C, Dickinson K, Cozzolino JP. Individual human tumors in short-term micro-organ cultures: Chemosensitivity testing by fluorescent cytoprinting. In Vitro Cell Dev Biol 1988; 24: 1137-1138.
25. Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 1990; 4: 567-571.
26. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6: 1121-1128.
27. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomatic colorimetric assay: assessment of radiosensitivity. Cancer Res 1987; 47: 943-946.
28. Twentyman PR, Fox NE, Rees JKH. Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 1989; 71: 19-24.
29. Pieters R, Huismans DR, Leyva A, Veerman AJP. Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 1989; 59: 217-220.
30. Pieters R, Huismans DR, Leyva A, Veerman AJP. Sensitivity to purine analogues in childhood leukemia assessed by the automated MTT-assay. Adv Exp Med Biol 1989; 253A: 447-454.
31. Kirkpatrick DL, Duke M, Goh TS. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res 1990; 14: 459-466.
32. Tsai CM, Ihde DC, Kadoyama C, Venzon D, Gazdar AF. Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Eur J Cancer 1990; 26: 1148-1152.
33. Dmitrovsky E, Seifter EJ, Gazdar AF, et al. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol 1990; 13: 285-289.
34. Hanson JA, Bentley DP, Bean EA, Nute SR, Moore JL. In vitro chemosensitivity testing in chronic lymphocytic leukaemia patients. Leuk Res 1991; 15: 565-569.
35. Rhedin AS, Tidefelt U, J”nsson K, Lundin A, Paul C. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993; 17: 271-276.
36. Nygren P, Hagberg H, Glimelius B, et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay. Ann Oncol 1994; 5 Suppl 1: S127-S131.
37. Leone LA, Meitner PA, Myers TJ, et al. Predictive value of the fluorescent cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy. Cancer Invest 1991; 9: 491-503.
38. Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumor Pharmacother 1988; 5: 253-257.
39. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-716.
40. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia. Cancer 1990; 65: 1263-1272.
41. Hongo T, Fujii Y, Yajima S. In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed chemotherapy. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug resistance in leukemia and lymphoma. Langhorne, PA: Harwood Academic Publishers, 1993: 319.
42. Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP. Is resistance to prednisolone in vitro related to the response to predniso(lo)ne in vivo at initial diagnosis in childhood acute lymphoblastic leukemia? - a preliminary analysis. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 321-328.
43. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177-185.
44. Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus 1990; 33: 295-298.
45. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 1986; 70: 1283-1295.
46. Langkjer ST, Norgaard JM. Use of the MTT-assay for evaluation of chemosensitivity in adult acute myeloid leukemia. In: Kaspers GJ, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 279-291.
47. Staib P, Lathan B, Schinkothe T, et al. . Prognosis in Adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index C1. Adv Exper Med Biol 1999; 457: 437-444.
48. Santini V, Bernabei PA, Dal Pozzo O, Santini S, Rossi Ferrini P. Acute myeloid leukemia (AML) sensitivity to antiblastics is predictable by INT assay. In: Kaspers GJ, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 365-368.
49. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989; 60: 206-10.
50. Stute N, Kohler T, Lehmann L. Drug resistance testing in acute myeloid leukemia. Adv Exper Med Biol 1999; 457: 445-452.
51. Larsson R, Jonsson B, Kristensen J, et al. Drug sensitivity testing of tumor cells from patients with acute leukemia and non-Hodgkin's lymphoma using a fluorometric microculture cytotoxicity assay. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 399-407.
52. Santini V, Bernabei PA, Silvestro L, et al. In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. Hematol Oncol 1989; 7: 287-93.
53. Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol 1989; 43: 374-384.
54. Blackman KE, Fingert HJ, Fuller AF, Meitner PA. The Fluorescent Cytoprint Assay in gynecologic malignancies and breast cancer: methodology and results. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 53-64.
55. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7: 630-635.
56. Koechli OR, Avner BP, Sevin B-U, et al. Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results. J Surg Oncol 1993; 54: 119-125.
57. Xu J-M, Song S-T, Tang Z-M, et al. . Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999; 53: 77-85.
58. Bosanquet AG, Copplestone JA, Johnson SA, et al. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. Br J Haematol 1999; 106: 474-476.
59. Silber R, Degar B, Costin D, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-3446.
60. Bosanquet AG. The DiSC assay - 10 years and 2000 tests further on. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 373-383.
61. Asanuma F, Yamada Y, Kawamura E, et al. [Comparison between clinical response and in vitro chemosensitivity of solid tumors in the succinic dehydrogenase inhibition test]. Gan To Kagaku Ryoho 1992; 19: 95-101.
62. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1: 305-311.
63. Imai S. Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer. Jpn J Cancer Chemother 1999; 26: 1289-1293.
64. Furukawa T, Kubota T, Suto A, et al. Clinical usefulness of chemosensitivity testing using the MTT assay. J Surg Oncol 1991; 48: 188-193.
65. Meitner PA. The fluorescent cytoprint assay: A new approach to in vitro chemosensitivity testing. Oncology (U S A ) 1991; 5: 75-82.
66. Smit EF, De Vries EGE, Meijer C, Mulder NH, Postmus PE. Limitations of the fast green assay for chemosensitivity testing in human lung cancer. Chest 1991; 100: 1358-1363.
67. Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer 1992; 65: 27-32.
68. Carstensen H, Tholander B. Chemosensitivity of ovarian carcinoma: In vitro/in vivo correlations using the dye exclusion assay of Weisenthal (meeting abstract). Proceedings: 3rd European Conference on Clinical Oncology 1985; Stockholm: p. 206-206. Click here to view abstract.
69. Ng TY, Ngan HYS, Cheng DKL, Wong LC. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynec Oncol 2000; 76: 405-408.
70. Konecny G, Crohns C, Pegram M, et al. . Correlation of drug response with the ATP tumorchemosensitivity assay in priamry FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77: 258-263.
71. Ohie S, Udagawa Y, Kozu A, et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 2000; 20: 2049-2054.
72. Sargent J, Elgie A, Taylor CG, Wilson J, Alton P, Hill JG. The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 64-75.
73. Sevin B-U, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer 1993; 71(Suppl): 1613-1620.
74. Sevin B-U, Perras JP, Koechli OR. Current status and future directions of chemosensitivity testing. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 179-194.
75. Taylor CG, Sargent JM, Elgie AW, et al. . The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev 1998; 22: 305-312.
76. Weisenthal LM. Predictive assays for drug and radiation resistance. In: Masters JM, ed. Cancer in Primary Culture: A Handbook (Developments in Oncology, V. 64). Dordrecht, The Netherlands: Kluwer Acad Publishers, 1991: 103-147.
77. Schrek R. Differences between responsive and intractable chronic lymphocytic leukemia. Med Hypotheses 1990; 31: 81-82.
78. Schrek R, Dolowy WC, Ammeraal RN. L-asparaginase: toxicity to normal and leukemic human lymphocytes. Science 1967; 155: 329-330.
79. Schrek R. Sensitivity of normal and leukemic lymphocytes and leukemic myeloblasts to heat. J Natl Cancer Inst 1966; 37: 649-654.
80. Schrek R, Leithold SL, Friedman IA, Best WR. Clinical evaluation of an in vitro test for radiosensitivity of leukemic lymphocytes. Blood 1962; 20: 432-442.
81. Schrek R. A method for counting the viable cells in normal and in malignant cell suspensions. Am J Cancer 1936; 28: 389-392.
82. Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RN. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res 1979; 39: 402-407.
83. Weisenthal LM, Marsden JA. A novel dye exclusion assay for predicting response to cancer chemotherapy. Proc Am Assoc Cancer Res 1981; 22: 155.(Abstract)
84. Weisenthal LM, Marsden JA, Malefatto J, Dill PL. Predicting response to cancer chemotherapy with a novel dye exclusion assay. Proceedings of XIIth International Congress of Chemotherapy,Florence,Italy 1981; (Abstract)
85. Bosanquet AG, Bird MC, Price WJ, Gilby ED. An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer 1983; 47: 781-789.
86. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994; 56: 715-720.
87. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
88. Pieters R, Kaspers GJ, Klumper E, Veerman AJ. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. Med Pediatr Oncol 1994; 22: 299-308.
89. Kaspers GJ, Kardos G, Pieters R, et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia 1994; 8: 1224-1229.
90. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
91. Hongo T, Fujii Y. In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay. Int J Hematol 1991; 54: 219-230.
92. Nagourney RA, Groncy PK, Oseas RS, Finklestein JZ, Weisenthal LM. Glucocorticoid sensitivity assessed in vitro: a new prognostic factor for relapse in childhood acute lymphoblastic leukemia (meeting abstract). Proc Am Soc Clin Oncol 1988; 7: A715.
93. Nagourney RA, Weisenthal LM. Dexamethasone-induced cell death in primary cultures of childhood A.L.L. predict survival: a prospective trial with 13 year follow-up. Leukemia 1995; 9: 531.
94. Kaspers GJL, Pieters R, Van Zantwijk CH, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
95. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
96. Pieters R, Kaspers GJL, Van Wering ER, et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
97. Veerman AJ. Cellular drug resistance in childhood leukemia. Ann Hematol 1994; 69: 31-34.
98. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751-756. 99. Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 813-818.
100. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two- tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999; 211: 233-238.
101. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
102. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van der Does-van den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266.
103. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
104. Klumper E, Ossenkoppele GJ, Pieters R, et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996; 93: 903-910.
105. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879-2886.
106. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6: 1121-1128.
107. Kristensen J, Jonsson B, Sundstrom C, Nygren P, Larsson R. In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. Med Oncol Tumor Pharmacother 1992; 9: 1-9.
108. Larsson R, Nygren P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res 1993; 13: 1825-1829.
109. Kristensen J, Jonsson B, Sundstrom C, Nygren P, Larsson R. In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia [published erratum appears in Med Oncol Tumor Pharmacother 1992;9(3):157]. Med Oncol Tumor Pharmacother 1992; 9: 65-74.
110. Larsson R, Fridborg H, Kristensen J, Sundstrom C, Nygren P. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer 1993; 67: 969-974.
111. Staib P, Schinkothe T, Henrichs T, et al. In vitro drug resistance testing may provide an independent prognostic factor for adult patients with AML. Proc Am Soc Hematol (ASH) Annual Meeting 1999; Abs # 269: (Abstract)
112. Hwang WS, Chen LM, Huang SH, Wang CC, Tseng MT. Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test. Leuk Res 1993; 17: 685-688.
113. Mollgard L, Tidefelt U, Sundman-Engberg B, Lofgren C, Paul C. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res 2000; 24: 445-452.
114. Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Long-term comparison of results of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms. Cancer 1988; 61: 1104-1109.
115. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-714.
116. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 1999; 106: 71-77.
117. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DISC assay. Acta Haematologica 1995; 93: 73-79.
118. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999; 34: 167-170.
119. Catchpoole DR, Stewart BW. Etoposide-induced cytotoxicity in two human T-cell leukemic lines: delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death. Cancer Res 1993; 53: 4287-4296.
120. Larsson R, Nygren P. Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. Eur J Cancer 1993; 29A: 1208-1212.
121. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999; 35: 424-432.
122. Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 1999; 15: 173-184.
123. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
124. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van der Does-van den Berg A. In vitro drug resistance profile: strongest prognostic factor in childhood acute lymphoblastic leukemia (ALL) (meeting abstract). Blood 1994; 84: 516a.
125. Veerman AJ, Kaspers GJ, Pieters R. Cellular drug resistance in childhood leukemia. Ann Hematol 1994; 69 Suppl 1: S31-S34.
126. Klumper E, Ossenkoppele GJ, Pieters R, et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996; 93: 903-910.
127. Norgaard JM, Langkjer ST, Palshof T, Pedersen B, Hokland P. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001; 66: 160-167.
128. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993; 90: 3294-3298.
129. Kerbel RS. Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis 1994; 14: 50-60.
130. Desoize B, Gimonet D, Jardiller JC. Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res 1998; 18: 4147-4158.
131. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000; 36: 193-207.
132. Shaw GL, Gazdar AF, Phelps R, et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 1993; 53: 5181-5187.
133. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1: 305-311.
134. Baba H, Takeuchi H, Inutsuka S, et al. Clinical value of SDI test for predicting effect of postoperative chemotherapy for patients with gastric cancer. Semin Surg Oncol 1994; 10: 140-144. 135. Markman M. Chemosensitivity and chemoresistance assays: are they clinically relevant? J Cancer Res Clin Oncol 1995; 121: 441-442.
136. Suto A, Kubota T, Shimoyama Y, Ishibiki K, Abe O. MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 1989; 42: 28-32.
137. Saikawa Y, Kubota T, Furukawa T, et al. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 1994; 85: 762-765.
138. Kurihara N, Kubota T, Furukawa T, et al. Chemosensitivity testing of primary tumor cells from gastric cancer patients with liver metastasis can identify effective antitumor drugs. Anticancer Res 1999; 19: 5155-5158.
139. Abe S, Kubota T, Matsuzaki SW, et al. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res 1999; 19: 4581-4586.
140. Fujita K, Kubota T, Matsuzaki SW, et al. Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res 1998; 18: 1973-1978.
141. Yamaue H, Tanimura H, Tsunoda T, et al. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 1991; 27: 1258-1263.
142. Yamaue H, Tanimura H, Noguchi K, et al. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 1992; 66: 794-799.
143. Yamaue H, Tanimura H, Nakamori M, et al. Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 1996; 39: 416-422.
144. Kimura H, Yonemura Y, Ohyama S, et al. The succinate dehydrogenase inhibition test for evaluating biopsy specimens and resected tumors of advanced gastric cancer. Surg Today 1992; 22: 508-511.
145. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 1987; 84: 5029-5033.
146. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
147. Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77: 258-263.
148. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9: 51-57.
149. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17: 1625-1631.
150. Link KH, Kornmann M, Butzer U, et al. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 2000; 89: 288-296.
151. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182.
152. McNeil C. Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic? J Natl Cancer Inst 1999; 91: 110-112.
153. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998.
154. Nelson NJ. Can HER2 status predict response to cancer therapy? J Natl Cancer Inst 2000; 92: 366-367.
155. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-1487.
156. Colombo N, ICON Collaborators MRC Clinical Trials Unit . Randomized trial of paclitaxel and carboplatin versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin, and cisplatin): The Third International Collaborative Ovarian Neoplasm Study (ICON3). Proc Annu Meet Am Soc Clin Oncol 2000; Abs # 1500: (Abstract)
157. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106-115.
158. Strauss E. Pretesting Tumors. Sci Am 1999; 280: 19-20.
159. Stein R. Official U.S. Government transcript of Health Care Finance Administration technology assessment committee meeting on Human Tumor Assay Systems, Baltimore, MD, November 15, 1999, Volume 1, pp. 92-99. Available on the internet: http://cms.hhs.gov/coverage/8b1-h1.asp Backup link: http://weisenthal.org/hcfa_1.htm
160. Nalick R. Official U.S. Government transcript of Health Care Finance Administration technology assessment meeting on Human Tumor Assay Systems, Baltimore, MD, Nov. 15, 1999, Volume 1, pp. 106-107. Available on the internet: http://cms.hhs.gov/coverage/8b1-h1.asp Backup link:http://weisenthal.org/hcfa_1.htm
161. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18: 2245-2249.
162. Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not in the clinic [editorial]. J Natl Cancer Inst 1992; 84: 466-469.
163. Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, and Hill JG. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 2001; 22:278-82  Click here to view abstract

Return to HTAJ Home Page
Return to Title/Abstract/Chapter Table of Contents
Return to Chapter 7: Editorial Conclusions